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Reconstructing Cancer’s Universe at the Dawn of the
21st Century
The early 21
st century was a time of renewed enthusiasm for finding
a cure for cancer. There was good reason to be optimistic. High-
-throughput technologies were being developed at an amazing speed.
For the first time in history, cancer researchers organized large inter-
national consortia and collaboration networks. It was clear that in
several years, it would be possible to profile hundreds if not thousands
of cancer tumor samples to determine which genes are mutated, ampli-
fied, deleted, methylated, or aberrantly transcribed in each individual
cancer. It was predicted that within a decade, we would know the entire
universe of every major cancer. The development of high-throughput
molecular technologies was not only a transformative event for science
but also for medicine. It was presumed that the molecular makeup of a
tumor correlates with clinical outcome and thus can be used to predict
prognosis and plan treatment approaches. Understanding the vulnera-
bilities of a tumor should enable physicians to not only predict which
patients are likely to respond to conventional therapies but also pin-
point new therapeutic targets in resistant patients. Many physicians
believed that the use of rational combinations of targeted therapies
based on an understanding of the genetic alterations that drive a patient’s
tumor would be more effective and less toxic. They embraced the idea
that "molecular oncology" would become routine in cancer care.
A decade later, we realized how naive we were. We have catalogued
the genome, transcriptome, epigenome, proteome and metabolome of
several common cancers, and additional information is compiled every
day as new technologies emerge. Unprecedented amounts of publically
available molecular data are mined by researchers around the world.
The hope was that profiling a large number of cancers would reveal
molecular alterations that are common to many cancers. Recurrent
alterations were not only likely to be important for cancer progression
but would also enable the targeting of a larger population of cancer
patients with the same drug. It was at this point that revelations about
the true behavior of cancer abounded.
The first surprise came with cancer gene sequence and copy number
analyses. We learned that each cancer contains tens, sometimes hund-
reds, of genetic abnormalities, many of which form redundant signal-
ing networks. It became clear that only combination therapies would be
successful in blocking the multi-pronged pathways that drive cancer
progression. Also disappointing was the discovery that very few genetic
alterations were common to more than a handful of cancers. The hope
for a universal cure for cancer was shattered and focus was turned to
"individualized" therapy.
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The exploration of patient-tailored, or individualized,
therapy led to the second surprise: the discovery of extre-
me intratumoral heterogeneity in each patient. Most tu-
mors consisted of multiple clones, each with different
combinations of genetic alterations. It was found that
molecularly targeted therapy that is effective in killing
cells in one clone may not be effective in another clone.
This may be the reason for frequent tumor recurrence
due to chemotherapy resistance. Therapy that was ini-
tially successful in eliminating most of the tumor bulk
may contribute to the evolution and expansion of tumor
clones that are driven by different molecular alterations.
Currently, our understanding of tumor plasticity is limit-
ed. The molecular profile data are only a snapshot in
tumor evolution. By the time we interpret the data and
decide upon the most rational therapeutic approach, the
tumor may have a completely different profile.
The third surprise involved the efforts to map all
coding RNAs, non-coding RNAs, epigenetic signatures,
and post-translational modifications in each individual
cancer. It was anticipated that these data would some-
how make sense once they fell into place, similar to
solving a 3-dimensional puzzle. However, instead of
bringing clarity to the puzzle, each "ome" added a new
layer of complexity. Genomic, epigenomic, proteomic,
and metabolomic data formed separate galaxies of infor-
mation with very little overlap. Future explorations of
tumor microenvironment and microbiome are likely to
document even more differences between individual can-
cers as well as changes within clones of the same cancer.
How are we going to integrate these galaxies of data to
reconstruct the comprehensive multi-dimensional uni-
verse of cancer? While the unexpectedly heterogeneous
and complex nature of cancer currently stands as an
obstacle to finding a cure, it is conceivable that new
developments in systems biology will have the power to
predict interacting pathways and identify the most vul-
nerable nodes that could serve as targets of intervention
and platforms for making therapeutic decisions.
Indeed, there is good reason to believe that a better
understanding of cancer will save lives. It has already
saved the lives of many patients with chronic myelo-
genous leukemia (CML). Diagnosis with CML was a
death sentence until 2001, when a new drug called Glee-
vec entered the clinic and changed the 5-year survival
rate to 95%. This drug targets a specific chromosomal
defect that is found in more than 90% of patients with
CML. Gleevec provides a proof-of-principle that ratio-
nally designed therapies work. It is probably not a coinci-
dence that researchers have been studying this cancer for
a very long time.
The story of rational therapy design for CML began
in 1960 with the discovery that cells from CML patients
had a specific chromosomal rearrangement, now known
as the Philadelphia chromosome. CML is a „simple”
cancer dominated by a single rearrangement resulting in
the fusion protein BCR-Abl, which is the sole driver of
the disease. Yet, it took us 40 years to combat this cancer.
It required improvements in microscopy and a better
understanding of chromosomes to identify the fusion
protein; a revolution in molecular biology for the func-
tional understanding of fusion proteins and their onco-
genic potential; the development of structural biology
and high-throughput chemical library screens; and co-
ordination of infrastructure between the basic researcher,
clinic, industry and government. Each of these technical
advancements took about a decade. Will it take 40 years
to develop rational therapies for cancers that we have just
started to understand at a molecular level? One thing
that we have learned from experience with Gleevec is
that knowledge eventually leads to life-saving therapies.
The sooner we start, the closer we are to success.
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